UY38926A - INHIBICIÓN DE INTEGRINA alfa4beta7 HUMANA - Google Patents
INHIBICIÓN DE INTEGRINA alfa4beta7 HUMANAInfo
- Publication number
- UY38926A UY38926A UY0001038926A UY38926A UY38926A UY 38926 A UY38926 A UY 38926A UY 0001038926 A UY0001038926 A UY 0001038926A UY 38926 A UY38926 A UY 38926A UY 38926 A UY38926 A UY 38926A
- Authority
- UY
- Uruguay
- Prior art keywords
- alfa4beta7
- inhibition
- human integrin
- integrin
- human
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Radio Relay Systems (AREA)
- Air Conditioning Control Device (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Moléculas pequeñas antagonistas de la integrina humana alfa4beta7, y métodos para usarlas en el tratamiento de varias enfermedades y afecciones.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962916062P | 2019-10-16 | 2019-10-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY38926A true UY38926A (es) | 2021-05-31 |
Family
ID=73198501
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001038926A UY38926A (es) | 2019-10-16 | 2020-10-16 | INHIBICIÓN DE INTEGRINA alfa4beta7 HUMANA |
Country Status (36)
| Country | Link |
|---|---|
| US (3) | US11104661B1 (es) |
| EP (3) | EP4559525A3 (es) |
| JP (7) | JP7437490B2 (es) |
| KR (2) | KR20220102669A (es) |
| CN (3) | CN115087444B (es) |
| AR (1) | AR120244A1 (es) |
| AU (2) | AU2020366435A1 (es) |
| BR (1) | BR112022007284A2 (es) |
| CA (1) | CA3154269A1 (es) |
| CL (1) | CL2022000959A1 (es) |
| CO (1) | CO2022005759A2 (es) |
| CR (1) | CR20220205A (es) |
| CU (1) | CU20220027A7 (es) |
| DK (1) | DK4045039T3 (es) |
| DO (2) | DOP2022000081A (es) |
| EC (1) | ECSP22038978A (es) |
| ES (1) | ES3035561T3 (es) |
| FI (1) | FI4045039T3 (es) |
| HR (1) | HRP20250749T1 (es) |
| HU (1) | HUE071814T2 (es) |
| IL (2) | IL319053A (es) |
| LT (1) | LT4045039T (es) |
| MA (1) | MA57399B1 (es) |
| MD (1) | MD4045039T2 (es) |
| MX (1) | MX2022004406A (es) |
| PE (1) | PE20221829A1 (es) |
| PH (1) | PH12022550886A1 (es) |
| PL (1) | PL4045039T3 (es) |
| PT (1) | PT4045039T (es) |
| RS (1) | RS66976B1 (es) |
| SI (1) | SI4045039T1 (es) |
| TW (6) | TWI775182B (es) |
| UA (1) | UA130059C2 (es) |
| UY (1) | UY38926A (es) |
| WO (3) | WO2021076902A1 (es) |
| ZA (2) | ZA202203872B (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202528300A (zh) | 2018-04-12 | 2025-07-16 | 美商莫菲克醫療股份有限公司 | 人類整合素α4β7拮抗劑 |
| WO2020092375A1 (en) | 2018-10-30 | 2020-05-07 | Gilead Sciences, Inc. | Quinoline derivatives as alpha4beta7 integrin inhibitors |
| US11578069B2 (en) | 2019-08-14 | 2023-02-14 | Gilead Sciences, Inc. | Compounds for inhibition of α4 β7 integrin |
| CN114585359B (zh) | 2019-10-16 | 2025-08-12 | 凯莫森特里克斯股份有限公司 | 用于治疗pd-l1疾病的杂芳基联苯酰胺 |
| MX2022004450A (es) | 2019-10-16 | 2022-05-03 | Chemocentryx Inc | Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1. |
| MA57399B1 (fr) * | 2019-10-16 | 2025-06-30 | Morphic Therapeutic, Inc. | Inhibition de l'intégrine humaine alpha4beta7 |
| WO2023125182A1 (zh) * | 2021-12-27 | 2023-07-06 | 海思科医药集团股份有限公司 | 一种丙酸衍生物及其在医药上的应用 |
| CN119836415A (zh) | 2022-09-09 | 2025-04-15 | 西藏海思科制药有限公司 | 一种丙酸衍生物及其在医药上的应用 |
| EP4638438A1 (en) | 2022-12-22 | 2025-10-29 | Xinthera, Inc. | Alpha4 beta7 integrin antagonists and uses thereof |
| KR20250152075A (ko) * | 2023-02-21 | 2025-10-22 | 씨4엑스 디스커버리 리미티드 | 거대환식 알파4베타7 인테그린 억제제 |
| AU2024279767A1 (en) | 2023-05-26 | 2025-12-04 | Adarx Pharmaceuticals, Inc. | Sod1-modulating compositions and methods of use thereof |
| WO2025026955A1 (en) * | 2023-07-28 | 2025-02-06 | Galapagos Nv | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| WO2025176107A1 (zh) * | 2024-02-20 | 2025-08-28 | 西藏海思科制药有限公司 | 一种吡啶酮衍生物及其在医药上的应用 |
| CN118702712B (zh) * | 2024-07-04 | 2025-11-11 | 安徽普利药业有限公司 | 一种n-(3-苯10硼酸)-l-天冬氨酸中间体制备方法 |
| CN119504796A (zh) * | 2024-11-20 | 2025-02-25 | 南通大学附属医院 | 一种具有抗肿瘤活性的化合物及其应用 |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE195117T1 (de) | 1993-03-31 | 2000-08-15 | Searle & Co | 1-amdinophenyl-pyrrolidone/piperidinone als blutblättchen-aggregations inhibitoren |
| DE4427979A1 (de) | 1993-11-15 | 1996-02-15 | Cassella Ag | Substituierte 5-Ring-Heterocyclen, ihre Herstellung und ihre Verwendung |
| US5849736A (en) | 1993-11-24 | 1998-12-15 | The Dupont Merck Pharmaceutical Company | Isoxazoline and isoxazole fibrinogen receptor antagonists |
| DE19622489A1 (de) | 1996-06-05 | 1997-12-11 | Hoechst Ag | Salze des 3-(2-(4-(4-(Amino-imino-methyl)-phenyl)-4- methyl-2,5-dioxo-imidazolidin-1-yl)-acetylamino)-3- phenyl-propionsäure-ethylesters |
| CA2268270A1 (en) | 1996-10-11 | 1998-04-23 | Cor Therapeutics, Inc. | Heterocyclic derivatives as factor xa inhibitors |
| CA2268381A1 (en) | 1996-10-11 | 1998-04-23 | Cor Therapeutics, Inc. | Selective factor xa inhibitors |
| DE19751251A1 (de) | 1997-11-19 | 1999-05-20 | Hoechst Marion Roussel De Gmbh | Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate |
| US6645939B1 (en) | 1997-11-24 | 2003-11-11 | Merck & Co., Inc. | Substituted β-alanine derivatives as cell adhesion inhibitors |
| EP1034164B1 (en) | 1997-11-24 | 2004-05-19 | Merck & Co., Inc. | Substituted beta-alanine derivatives as cell adhesion inhibitors |
| MY153569A (en) | 1998-01-20 | 2015-02-27 | Mitsubishi Tanabe Pharma Corp | Inhibitors of ?4 mediated cell adhesion |
| DE19821483A1 (de) | 1998-05-14 | 1999-11-18 | Hoechst Marion Roussel De Gmbh | Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| WO2000000481A1 (en) | 1998-06-29 | 2000-01-06 | Du Pont Pharmaceuticals Company | Cyclic carbamates and isoxazolidines as iib/iiia antagonists |
| WO2000006169A1 (en) * | 1998-07-29 | 2000-02-10 | Merck & Co., Inc. | Integrin receptor antagonists |
| GB9826174D0 (en) * | 1998-11-30 | 1999-01-20 | Celltech Therapeutics Ltd | Chemical compounds |
| US6972296B2 (en) | 1999-05-07 | 2005-12-06 | Encysive Pharmaceuticals Inc. | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors |
| US6723711B2 (en) | 1999-05-07 | 2004-04-20 | Texas Biotechnology Corporation | Propanoic acid derivatives that inhibit the binding of integrins to their receptors |
| AU4826900A (en) | 1999-05-07 | 2000-11-21 | Texas Biotechnology Corporation | Propanoic acid derivatives that inhibit the binding of integrins to their receptors |
| DE60035204T2 (de) | 1999-09-24 | 2008-02-21 | Genentech, Inc., South San Francisco | Tyrosinderivate |
| DE10041423A1 (de) | 2000-08-23 | 2002-03-07 | Merck Patent Gmbh | Biphenylderivate |
| BR0113671A (pt) * | 2000-08-30 | 2004-01-06 | Pharmacia Corp | Antagonistas de integrina alfa v beta 3 gem-substituìda |
| DE10111876A1 (de) | 2001-03-10 | 2002-09-19 | Aventis Pharma Gmbh | Bis(trifluormethyl)hydantoine als Zwischenprodukte für pharmazeutische Wirkstoffe |
| DE10154280A1 (de) | 2001-11-05 | 2003-05-15 | Wilex Ag | Antagonisten für alpha¶4¶-Integrine |
| KR20040105740A (ko) | 2002-02-25 | 2004-12-16 | 엘란 파마슈티칼스, 인크. | 염증 치료제의 투여 방법 |
| EP1784426B1 (en) | 2004-09-03 | 2011-11-23 | Genentech, Inc. | Humanized anti-beta7 antagonists and uses therefor |
| US7972775B2 (en) | 2005-03-03 | 2011-07-05 | Seedlings Life Science Ventures, Llc | Method of risk management for patients undergoing Natalizumab treatment |
| WO2006126529A1 (ja) | 2005-05-25 | 2006-11-30 | Shionogi & Co., Ltd. | ６，７－不飽和－７－カルバモイル置換モルヒナン誘導体 |
| NZ563739A (en) | 2005-06-09 | 2009-12-24 | Ucb Pharma Sa | 2,6 Quinolinyl derivatives, processes for preparing them and their use as medicament |
| LT2676967T (lt) | 2006-02-28 | 2019-09-10 | Biogen Ma Inc. | Uždegiminių ir autoimuninių ligų gydymo būdai su natalizumabu |
| WO2010091411A1 (en) | 2009-02-09 | 2010-08-12 | Glaxosmithkline Llc | Piperidinyl cyclic amido antiviral agents |
| SG193565A1 (en) | 2011-03-31 | 2013-11-29 | Genentech Inc | Methods of administering beta7 integrin antagonists |
| RU2015112024A (ru) | 2012-10-05 | 2016-11-27 | Дженентек, Инк. | Способы диагностики и лечения воспалительного заболевания кишечника |
| JP7054990B2 (ja) | 2014-03-27 | 2022-04-15 | ジェネンテック， インコーポレイテッド | 炎症性腸疾患の診断及び治療のための方法 |
| WO2016011940A1 (zh) | 2014-07-25 | 2016-01-28 | 江苏恒瑞医药股份有限公司 | 氮茚-酰胺类衍生物、其制备方法及其在医药上的应用 |
| WO2016086147A1 (en) * | 2014-11-26 | 2016-06-02 | Millennium Pharmaceuticals, Inc. | Vedolizumab for the treatment of fistulizing crohn's disease |
| AR103782A1 (es) | 2015-02-26 | 2017-05-31 | Genentech Inc | ANTAGONISTAS DE INTEGRINA b7 Y MÉTODOS DE TRATAMIENTO DE LA ENFERMEDAD DE CROHN |
| BR112019017929A2 (pt) * | 2017-02-28 | 2020-05-19 | Morphic Therapeutic Inc | inibidores de integrina (alfa-v)(beta-6) |
| US10246451B2 (en) | 2017-04-26 | 2019-04-02 | Aviara Pharmaceuticals, Inc. | Propionic acid derivatives and methods of use thereof |
| US10875875B2 (en) * | 2017-04-26 | 2020-12-29 | Aviara Pharmaceuticals, Inc. | Propionic acid derivatives and methods of use thereof |
| TW202528300A (zh) | 2018-04-12 | 2025-07-16 | 美商莫菲克醫療股份有限公司 | 人類整合素α4β7拮抗劑 |
| US11179383B2 (en) | 2018-10-30 | 2021-11-23 | Gilead Sciences, Inc. | Compounds for inhibition of α4β7 integrin |
| ES3013256T3 (en) | 2018-10-30 | 2025-04-11 | Gilead Sciences Inc | Imidazo[1,2-a]pyridine derivatives as alpha4beta7 integrin inhibitors for the treatment of inflammatory diseases |
| WO2020092375A1 (en) | 2018-10-30 | 2020-05-07 | Gilead Sciences, Inc. | Quinoline derivatives as alpha4beta7 integrin inhibitors |
| CN112996786B (zh) * | 2018-10-30 | 2024-08-20 | 吉利德科学公司 | 用于抑制α4β7整合素的化合物 |
| MA57399B1 (fr) * | 2019-10-16 | 2025-06-30 | Morphic Therapeutic, Inc. | Inhibition de l'intégrine humaine alpha4beta7 |
-
2020
- 2020-10-16 MA MA57399A patent/MA57399B1/fr unknown
- 2020-10-16 TW TW109136036A patent/TWI775182B/zh active
- 2020-10-16 US US17/072,797 patent/US11104661B1/en active Active
- 2020-10-16 ES ES20875989T patent/ES3035561T3/es active Active
- 2020-10-16 PT PT208759894T patent/PT4045039T/pt unknown
- 2020-10-16 KR KR1020227015040A patent/KR20220102669A/ko active Pending
- 2020-10-16 JP JP2022509595A patent/JP7437490B2/ja active Active
- 2020-10-16 JP JP2022523102A patent/JP7437495B2/ja active Active
- 2020-10-16 MD MDE20220933T patent/MD4045039T2/ro unknown
- 2020-10-16 PL PL20875989.4T patent/PL4045039T3/pl unknown
- 2020-10-16 DK DK20875989.4T patent/DK4045039T3/da active
- 2020-10-16 EP EP25157767.2A patent/EP4559525A3/en active Pending
- 2020-10-16 CA CA3154269A patent/CA3154269A1/en active Pending
- 2020-10-16 FI FIEP20875989.4T patent/FI4045039T3/fi active
- 2020-10-16 BR BR112022007284A patent/BR112022007284A2/pt unknown
- 2020-10-16 HU HUE20875989A patent/HUE071814T2/hu unknown
- 2020-10-16 PH PH1/2022/550886A patent/PH12022550886A1/en unknown
- 2020-10-16 CN CN202080088450.4A patent/CN115087444B/zh active Active
- 2020-10-16 TW TW112116098A patent/TWI857592B/zh active
- 2020-10-16 IL IL319053A patent/IL319053A/en unknown
- 2020-10-16 WO PCT/US2020/056001 patent/WO2021076902A1/en not_active Ceased
- 2020-10-16 SI SI202030622T patent/SI4045039T1/sl unknown
- 2020-10-16 AR ARP200102870A patent/AR120244A1/es unknown
- 2020-10-16 PE PE2022000633A patent/PE20221829A1/es unknown
- 2020-10-16 RS RS20250645A patent/RS66976B1/sr unknown
- 2020-10-16 MX MX2022004406A patent/MX2022004406A/es unknown
- 2020-10-16 HR HRP20250749TT patent/HRP20250749T1/hr unknown
- 2020-10-16 WO PCT/US2020/055986 patent/WO2021076890A1/en not_active Ceased
- 2020-10-16 CU CU2022000027A patent/CU20220027A7/es unknown
- 2020-10-16 UY UY0001038926A patent/UY38926A/es unknown
- 2020-10-16 TW TW111127993A patent/TWI802477B/zh active
- 2020-10-16 LT LTEPPCT/US2020/055986T patent/LT4045039T/lt unknown
- 2020-10-16 AU AU2020366435A patent/AU2020366435A1/en active Pending
- 2020-10-16 US US17/769,003 patent/US20240174632A1/en active Pending
- 2020-10-16 CN CN202411308053.XA patent/CN119192137A/zh active Pending
- 2020-10-16 CR CR20220205A patent/CR20220205A/es unknown
- 2020-10-16 EP EP20875989.4A patent/EP4045039B1/en active Active
- 2020-10-16 UA UAA202201185A patent/UA130059C2/uk unknown
-
2021
- 2021-07-16 US US17/378,282 patent/US11370773B1/en active Active
- 2021-10-15 JP JP2021576053A patent/JP7209116B2/ja active Active
- 2021-10-15 TW TW110138309A patent/TWI791304B/zh active
- 2021-10-15 TW TW113110859A patent/TWI888065B/zh active
- 2021-10-15 AU AU2021361031A patent/AU2021361031A1/en active Pending
- 2021-10-15 TW TW111149835A patent/TWI840047B/zh active
- 2021-10-15 EP EP21881178.4A patent/EP4228634A4/en active Pending
- 2021-10-15 WO PCT/US2021/055196 patent/WO2022081983A1/en not_active Ceased
- 2021-10-15 KR KR1020237015039A patent/KR20230088376A/ko active Pending
- 2021-10-15 CN CN202180083775.8A patent/CN116783161A/zh active Pending
-
2022
- 2022-04-05 ZA ZA2022/03872A patent/ZA202203872B/en unknown
- 2022-04-13 DO DO2022000081A patent/DOP2022000081A/es unknown
- 2022-04-14 CL CL2022000959A patent/CL2022000959A1/es unknown
- 2022-04-14 IL IL292296A patent/IL292296B2/en unknown
- 2022-05-02 CO CONC2022/0005759A patent/CO2022005759A2/es unknown
- 2022-05-16 EC ECSENADI202238978A patent/ECSP22038978A/es unknown
-
2023
- 2023-01-06 JP JP2023000761A patent/JP7500785B2/ja active Active
- 2023-03-30 ZA ZA2023/03992A patent/ZA202303992B/en unknown
-
2024
- 2024-02-09 JP JP2024018866A patent/JP7702004B2/ja active Active
- 2024-02-09 JP JP2024018765A patent/JP7717202B2/ja active Active
- 2024-06-05 JP JP2024091304A patent/JP2024116230A/ja active Pending
-
2025
- 2025-02-19 DO DO2025000034A patent/DOP2025000034A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY38926A (es) | INHIBICIÓN DE INTEGRINA alfa4beta7 HUMANA | |
| CL2019003144A1 (es) | Formulaciones de anticuerpos anti-lag3 y co-formulaciones de anticuerpos anti-lag3 y anticuerpos anti-pd-1. | |
| MX2022009056A (es) | Inhibidores de integrina ?v?6. | |
| CL2019001874A1 (es) | Inhibidores de tgfß1 isoforma-específicos contexto-permisivos y uso de los mismos. | |
| CO2017005784A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
| SV2018005610A (es) | Derivados de oxopiridina sustituidos | |
| CL2018002814A1 (es) | Composiciones y metodos para el tratamiento de heridas, trastornos, y enfermedades de la piel. | |
| UY38353A (es) | Inhibición de integrina alfavbeta6 | |
| DOP2015000304A (es) | Inhibidores cristalinos de bromodominios | |
| CO2017007121A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
| MX382033B (es) | Compuestos heterocíclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma. | |
| EA201791884A1 (ru) | Химерные антигенные рецепторы против dll3 и способы применения | |
| CL2016001895A1 (es) | Compuestos | |
| UY34278A (es) | Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades | |
| BR112019005139A2 (pt) | anticorpos anti-il-33 e usos dos mesmos | |
| ECSP13012648A (es) | Inmunoglobulinas con dominio variable dual y usos de las mismas | |
| DOP2013000047A (es) | Inmunoglobulinas con dominio variable dual y usos de las mismas | |
| UY33707A (es) | Inmunoglobulinas con dominio variable dual y usos de las mismas | |
| UY33492A (es) | Inmunoglobulinas con dominio variable dual y usos de las mismas | |
| CR20130058A (es) | Inmunoglobulinas con dominio variable dual y usos de las mismas | |
| DOP2016000109A (es) | Formas sólidas de ácido {[5-(3-clorofenil) -3-hidroxipiridin-2-carbonil] amino} acético, composiciones, y usos de las mismas. | |
| CL2015002835A1 (es) | Nuevos derivados de piridina | |
| MX2022002954A (es) | Anticuerpos anti-htra1 y metodos de uso de los mismos. | |
| MX2020011100A (es) | Compuestos, composiciones farmaceuticas y metodos de uso de agonistas de ppar. | |
| MX2017006953A (es) | Medicamentos para disminuir la evolucion de la enfermedad de parkinson. |